Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies (Q35036208)

5 August 2017

1 reference

title

Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies (English)

1 reference

idiopathic inflammatory myopathy

5 August 2017

main subject

1 reference

Lisa G Rider

1

1 reference

5 August 2017

language of work or name

1 reference

1 November 2002

1 reference

Rheumatic Diseases Clinics of North America

5 August 2017

published in

1 reference

5 August 2017

volume

28

1 reference

5 August 2017

issue

4

1 reference

5 August 2017

page(s)

935-977

1 reference

Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Preliminary definition of improvement in juvenile arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

The idiopathic inflammatory myopathies: spectrum of MR imaging findings

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Quantitative assessment of myositis in thigh muscles using magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Methotrexate treatment of recalcitrant childhood dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Normative values for isometric muscle force measurements obtained with hand-held dynamometers

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Measuring knee extensor muscle strength

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Pulmonary hypertension in polymyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Cyclosporin in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Reference values of maximum isometric muscle force obtained in 270 children aged 4–16 years by hand-held dynamometry

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

1 reference

7 January 2021

Simple method for measurement of lower extremity muscle strength

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Decreased aerobic capacity in children with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

The utility of isokinetic dynamometry in the assessment of human muscle function.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

The five item Barthel index

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Tacrolimus in refractory polymyositis with interstitial lung disease

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

The clinical meaning of functional outcome scores in children with juvenile arthritis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Correlation between tests of muscle involvement and clinical muscle weakness in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Creatine kinase activity inhibitor in sera from patients with muscle disease

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Serum skeletal troponin I in inflammatory muscle disease: relation to creatine kinase, CKMB and cardiac troponin I.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Extramuscular manifestations in idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Radiologic evaluation of the dysphagic patient

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Diagnosis and management of gastrointestinal perforations in childhood dermatomyositis with particular reference to perforations of the duodenum

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

CT and MR imaging findings of bowel ischemia from various primary causes.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

MRI of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Novel gastrointestinal tract manifestations in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

A curable cause of chronic idiopathic intestinal pseudo-obstruction in children: idiopathic myositis of the small intestine

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Interstitial lung disease in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Clinical assessment of the respiratory muscles

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Polymyositis-dermatomyositis-associated interstitial lung disease

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Use of sequential DTPA clearance and high resolution computerized tomography in monitoring interstitial lung disease in dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Serum KL-6 in adult patients with polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/dermatomyositis with interstitial pneumonia

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Quantitative CT of the lung

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Pulmonary and cardiac manifestations of polymyositis-dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Cardiac and skeletal muscle scintigraphy in dermato- and polymyositis: clinical implications

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

New application of myocardial antimyosin scintigraphy: diagnosis of myocardial disease in polymyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Magnetic resonance imaging evaluation of myocardial and pericardial disease

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Magnetic resonance imaging appearance of the muscles in childhood dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Juvenile idiopathic inflammatory myopathies: the value of magnetic resonance imaging in the detection of muscle involvement

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Cost-effectiveness of MR imaging in evaluating polymyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Magnetic resonance imaging of primary skeletal muscle diseases: patterns of distribution and severity of involvement

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Dermatomyositis with normal muscle enzyme concentrations. A single-blind study of the diagnostic value of magnetic resonance imaging and ultrasound

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

MR imaging in amyopathic dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Muscle imaging in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Muscular ultrasound in idiopathic inflammatory myopathies of adults

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Skeletal muscle sonography: a correlative study of echogenicity and morphology

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Real-time ultrasound imaging of muscles

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Magnesium abnormalities of skeletal muscle in dermatomyositis and juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis. Altered energy utilization during exercise

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Antimyosin scintigraphy compared with magnetic resonance imaging in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Diagnosis of idiopathic myositis: value of 99m technetium pyrophosphate muscle scintigraphy and magnetic resonance imaging in targeted muscle biopsy

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

CT muscle imaging and the clinical assessment of neuromuscular disease.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

T-lymphocyte immunophenotyping in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Soluble CD4, CD8 in patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Elevated circulating soluble CD30 levels in patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Activation of complement and coagulation in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Elevated soluble intercellular adhesion molecules-1 in inflammatory myopathy

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Serum concentrations of vascular endothelial growth factor in collagen diseases

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Serum concentrations of basic fibroblast growth factor in collagen diseases

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Increased serum concentration of hyaluronate in dermatomyositis patients

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Serum concentrations of carboxyterminal propeptide of type 1 procollogen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Elevated serum levels of manganese superoxide dismutase in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Quantitative electromyography in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Inter- and intraobserver variation in the interpretation of electromyographic tests

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Muscle pathology in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage?: a prospective study.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Sarcopenia: assessment of muscle mass

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Late progression in dermatomyositis in childhood

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Milk of calcium fluid collections in juvenile dermatomyositis: MR characteristics

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

MYOSITIS OSSIFICANS NON-PROGRESSIVA–REVERSIBLE MUSCLE CALCIFICATION IN POLYMYOSITIS

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Scintigraphic evaluation of calcinosis in juvenile dermatomyositis with Tc-99m MDP

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Extensive soft-tissue involvement of dermatomyositis detected by whole-body scintigraphy with 99mTc-MDP and 201TL-chloride

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(02)50027-3

7 January 2021

10.1016/S0889-857X(02)00027-3

Identifiers

DOI

1 reference

5 August 2017

1 reference